

APPENDIX

6. The G-CSF formulation of [any one of] Claim[s] 1 [to 5], which is substantially free from protein as a stabilizer.
7. The G-CSF formulation of [any one of] Claim[s] 1 [to 6] in the form of a lyophilized formulation.
8. The G-CSF formulation of [any one of] Claim[s] 1 [to 7] further containing mannitol.
9. The G-CSF formulation of [any one of] Claim[s] 1 [to 8] further containing a surfactant.
12. The G-CSF formulation of [any one of] Claim[s] 1 [to 11], which has a pH of 5-7.
15. The G-CSF formulation of [any one of] Claim[s] 1 [to 14] wherein G-CSF is produced from CHO cells.
18. The G-CSF formulation of Claim 15 [or 16], which has a pH of 6.5.
21. The G-CSF formulation of Claim 19 [or 20], which is substantially free from protein as a stabilizer.
26. The method of [any one of] Claim[s] 22 [to 25] wherein other proteins are not present as stabilizers.
27. The method of [any one of] Claim[s] 22 [to 26] wherein said composition containing a physiologically active protein having a methionine residue is lyophilized or in the form of a solution.
30. The composition of Claim 28 [or 29], which is substantially free from other proteins as stabilizers.